where is retatrutide approved produces up to 30.3% weight loss in Phase 3 trial Retatrutide, an experimental weight-loss drug,

We need to go slow and make sure that you don't have any problems such as low blood sugar. Resources We Trust New Analysis Examines Long-Term Outcomes of GLP-1 Therapies in Type 1 Diabetes Cleveland Clinic: Mayo Clinic: Weigh Benefits, Risks Carefully Before Taking Off-Label Medication T1D Exchange: Understanding Off-Label Use of GLP-1 (Glucagon-Like Peptide-1 Receptor) Agonists Among Providers Participating in the T1D Exchange Quality Improvement Collaborative (T1DX-QI) SGLT2 Inhibitors in Type 1 Diabetes Where Do We Stand in 2025

Microdosing is the practice of taking a small fraction of a standard dose of a substance

Retatrutide is not recommended during pregnancy or breastfeeding

How GLP-1s Offer Real-World Heart Protection The evidence that GLP1-s reduce the risk of heart attack and stroke comes from large cardiovascular outcomes trials designed to measure what researchers call MACE, major adverse cardiovascular events